+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Non-Cystic Fibrosis Bronchiectasis - Global Strategic Business Report

  • PDF Icon

    Report

  • 396 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6106394
The global market for Non-Cystic Fibrosis Bronchiectasis was estimated at US$3.6 Billion in 2024 and is projected to reach US$4.5 Billion by 2030, growing at a CAGR of 3.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Non-Cystic Fibrosis Bronchiectasis market.

Global Non Cystic Fibrosis Bronchiectasis Market - Key Trends & Drivers Summarized

How Is Disease Awareness Driving Clinical Recognition?

Non cystic fibrosis bronchiectasis is a chronic respiratory condition marked by irreversible airway dilation, frequent infections, and persistent sputum production. It often goes undiagnosed due to overlapping symptoms with COPD, asthma, or recurrent respiratory infections. Recent improvements in diagnostic imaging, particularly high-resolution CT scans, have led to better recognition of bronchiectasis as a distinct condition. As awareness grows among pulmonologists and general practitioners, more cases are being identified and accurately managed.

Continuing medical education and updated clinical guidelines have played a pivotal role in raising awareness. Physicians are now more likely to consider bronchiectasis in patients with recurrent respiratory symptoms. Patient education campaigns and respiratory societies are also encouraging individuals with chronic cough and sputum to seek evaluation, further supporting earlier detection of the disease.

What Treatment Innovations Are Emerging in Disease Management?

Treatment for non cystic fibrosis bronchiectasis traditionally focuses on airway clearance techniques, antibiotics, and managing exacerbations. However, several novel therapeutic approaches are evolving. Inhaled macrolides and long acting antibiotics are being refined to minimize systemic exposure while improving airway microbiome management. Additionally, mucoactive agents and hyperosmolar saline formulations are being tailored for more effective mucus clearance.

Research into targeted anti inflammatory therapies and biologics designed to modulate neutrophil pathways is also underway. These treatments aim to reduce chronic inflammation without compromising host defense. Furthermore, new non invasive ventilation and airway clearance devices are emerging, providing personalized respiratory support and improving patient quality of life. Supportive programs, such as supervised exercise and pulmonary rehabilitation, are being integrated into treatment regimens to reduce exacerbation frequency and promote lung function.

Why Are Patient-Centric and Multidisciplinary Care Models on the Rise?

Effective management of non cystic fibrosis bronchiectasis requires a comprehensive, patient centric approach. Multidisciplinary teams - including pulmonologists, physiotherapists, infectious disease specialists, and nutritionists - are becoming standard in respiratory clinics and care centers. These teams coordinate airway clearance plans, antibiotic regimens, nutritional counseling, and comorbidity management to optimize outcomes.

Digital care tools have also enhanced patient support. Mobile apps help track symptoms, medication adherence, and physiotherapy routines. Telehealth consultations and remote monitoring enable timely intervention during exacerbations, reducing hospital readmissions. Patient support communities and disease registries are further strengthening treatment continuity and real world data collection efforts.

Growth in the non cystic fibrosis bronchiectasis market is driven by several factors.

Rising clinical awareness and improved diagnostic imaging are expanding detection rates and broadening patient pools. Development of targeted inhaled antibiotics, anti inflammatory agents, and mucus clearing therapies is enhancing treatment options. Integration of multidisciplinary care models and digital health platforms is improving management effectiveness and patient engagement. Additionally, clinical trials evaluating novel biologics and airway support devices are fueling pipeline activity. Greater emphasis on chronic respiratory disease management by public health systems continues to support investment in bronchiectasis care infrastructure and therapies.

Scope Of Study:

The report analyzes the Non-Cystic Fibrosis Bronchiectasis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Treatment (Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment, Other Treatments); Diagnosis (CT Scan Diagnosis, Bronchoscopy Diagnosis, Chest X-Ray Diagnosis, Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Surgery Treatment segment, which is expected to reach US$1.3 Billion by 2030 with a CAGR of a 5.2%. The Physiotherapy Treatment segment is also set to grow at 2.3% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $979.7 Million in 2024, and China, forecasted to grow at an impressive 7.3% CAGR to reach $920.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Non-Cystic Fibrosis Bronchiectasis Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Non-Cystic Fibrosis Bronchiectasis Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Non-Cystic Fibrosis Bronchiectasis Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Armata Pharmaceuticals, AstraZeneca plc, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., CSL Behring and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Non-Cystic Fibrosis Bronchiectasis market report include:

  • Armata Pharmaceuticals
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • CSL Behring
  • GlaxoSmithKline plc
  • Haisco Pharmaceutical Group
  • Infex Therapeutics
  • Insmed Incorporated
  • NovaBiotics
  • Novartis AG
  • Parion Sciences Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Renovion Inc.
  • Sanofi S.A.
  • SolAeroMed Inc.
  • Teva Pharmaceutical Industries
  • Verona Pharma plc
  • Zambon S.p.A.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Non-Cystic Fibrosis Bronchiectasis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Diagnosis Rates of Chronic Respiratory Conditions Drive Attention Toward Non-Cystic Fibrosis Bronchiectasis
  • Increased Use of High-Resolution CT Scans Enhances Detection and Differentiation of Non-CF Bronchiectasis
  • Growing Geriatric Population and Associated Lung Disorders Spur Market Demand for Long-Term Respiratory Care
  • Rising Incidence of Recurrent Respiratory Infections Throws the Spotlight on Early-Stage Identification and Treatment
  • Expansion of Multidisciplinary Care Models Supports Comprehensive Management of Non-CF Bronchiectasis Patients
  • Adoption of Inhaled Antibiotic Therapies Strengthens Targeted Treatment Strategies for Infection Control
  • Ongoing Clinical Trials Exploring Anti-Inflammatory Agents Stimulate Pipeline Innovation
  • Increased Use of Airway Clearance Devices and Nebulizer Systems Enhances Symptom Management
  • Focus on Reducing Hospital Readmission Rates Drives Use of Maintenance Therapies and Prophylactic Treatments
  • Growing Research into Non-Tuberculous Mycobacterial (NTM) Infections Linked to Bronchiectasis Expands Therapeutic Approaches
  • Integration of Personalized Care Protocols Supports Better Outcomes and Patient Adherence
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Non-Cystic Fibrosis Bronchiectasis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Physiotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Physiotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Physiotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Vaccination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Vaccination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Vaccination Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Airway Pharmacotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Airway Pharmacotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Airway Pharmacotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Antibiotics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Lung Function Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Lung Function Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Lung Function Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Sputum Culture Test Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Sputum Culture Test Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Sputum Culture Test Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Blood Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Blood Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Blood Tests Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Other Diagnosis Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for CT Scan Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for CT Scan Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for CT Scan Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Bronchoscopy Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Bronchoscopy Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Bronchoscopy Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Chest X-Ray Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Chest X-Ray Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Chest X-Ray Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Armata Pharmaceuticals
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • CSL Behring
  • GlaxoSmithKline plc
  • Haisco Pharmaceutical Group
  • Infex Therapeutics
  • Insmed Incorporated
  • NovaBiotics
  • Novartis AG
  • Parion Sciences Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Renovion Inc.
  • Sanofi S.A.
  • SolAeroMed Inc.
  • Teva Pharmaceutical Industries
  • Verona Pharma plc
  • Zambon S.p.A.

Table Information